Treatment Catalog | Blog | Supplements | Patient Portal | Get the App

(980) 290-1297

Premier Hormone Health & Wellness

Scar PT Gel

Overview of Scar PT Gel

Dosage Strength

Pentoxifylline / Triamcinolone Acetonide 0.5/0.1% 30 mL Pump

General Information

Pentoxifylline
Pentoxifylline is a synthetic dimethylxanthine derivative related to theophylline and caffeine in structure. Unlike these drugs, pentoxifylline has hematological effects that make it effective in the symptomatic treatment of peripheral vascular disease sequelae. Pentoxifylline has also been used to treat chronic and acute cerebrovascular insufficiency, sickle cell disease1, and severe diabetic neuropathy. 2 The FDA authorized pentoxifylline in August 1984.

Triamcinolone Acetonide
When taken orally, triamcinolone is a synthetic glucocorticoid that is slightly more potent than prednisone. Triamcinolone has limited mineralocorticoid action and is therefore not used systemically to treat adrenal insufficiency unless combined with a more strong mineralocorticoid. Triamcinolone is marketed commercially in nasal, parenteral, topical, and intravitreal injectable forms. Triamcinolone oral and respiratory formulations were once available but are no longer available in the United States. When intra-articular therapy is indicated, triamcinolone injections are often employed. The nasal spray is used to treat seasonal and perennial allergies. Topical treatments for corticosteroid-responsive dermatoses are of medium or high potency.

References

1.Dennenhoffer MA, Rozek S. Pentoxifylline in sickle cell anemia. Drug Intel Clin Pharm 1987;21:620.
2.Vinik AI, Holland MT, Le Beau JM, et al. Diabetic neuropathies. Diabetes Care 1992;15:1926-75.
3.Schimmer B, Parker K. Adrenocorticotropic hormone; adrenocortical steroids and their synthetic analogs; inhibitors of the synthesis and actions of adrenocortical hormones. In: Hardman JG, Limbird LE, Molinoff PB, et al., eds. Goodman and Gilman’s the Pharmacological Basis of Therapeutics, 10th edition. New York: McGraw Hill, 2001;1649-1674.
4.Barnes PJ. Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond). 1998;94(6):557-572.
5.National Asthma Education and Prevention Program Expert Panel 3. Expert panel report 3: guidelines for the diagnosis and management of asthma. Bethesda (MD): National Institutes of Health. National Heart, Lung, and Blood Institute; 2007 Aug. NIH Publication No. 07-4051.
6.Paap CM, Simpson KS, Horton MW, et al. Multiple-dose pharmacokinetics of pentoxifylline and its metabolites during renal insufficiency. Ann Pharmacother 1996;30:724-9.
7.Ward A, Clissold SP. Pentoxifylline. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs 1987;34:50-97.
8.Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med 2017;377:644–57.
9.Pentoxifylline (Trental) tablets package insert. Bridgewater, NJ: Sanofi-Aventis U.S. LLC; Oct 2007.
10.Witter FR, Smith RV. The excretion of pentoxifylline and its metabolites into human breast milk. Am J Obstet Gynecol. 1985;151:1094-7.
11.Bond DW, Charlton CPJ. Benign intracranial hypertension secondary to nasal fluticasone propionate. BMJ 2001;322 (7291):987.
12.Patradoon-Ho P, Gunasekera H, Ryan MM. Inhaled corticosteroids, adrenal suppression and benign intracranial hypertension. Med J Aust 2006;185:279-280
13.Triamcinolone acetonide ointment package insert. Melville, NY: E. Fougera & Co., 2011 Oct.
14.Azmacort (triamcinolone acetonide) package insert. North Chicago, IL: Abbott Laboratories; 2007 Sept.
15.Kenalog-40 (triamcinolone acetonide) injection package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2018 Mar.
16.Shulman DI, Palmert MR, Kemp SF. Adrenal insufficiency: still a cause of morbidity and death in childhood. Pediatrics 2007;119(2):e484-494.
17.Triamcinolone acetonide cream package insert. Melville, NY: E. Fougera & Co.; 2011 Sept
18.Nasacort AQ (triamcinolone acetonide) nasal spray package insert. Bridgewater, NJ: Sanofi-aventis U.S. LLC; 2013 July.
19.Nasacort Allergy 24HR (triamcinolone acetonide) OTC nasal spray package insert. Chattanooga, TN: Chattem, Inc., a wholly-owned subsidiary of Sanofi-Aventis; 2016 Sept.
20.Zilretta (triamcinolone acetonide extended-release injectable suspension). Burlington, MA: Flexion Therapeutics, Inc.; 2019 Dec.
21.Hengge UR, Ruzicka T, Schwartz RA. Adverse effects of topical glucocorticosteroids. J Am Acad Dermatol 2006;54:1-15.
22.Morley KW, Dinulos JG. Update on topical glucocorticoid use in children. Curr Opin Pediatr 2012;24(1):121-128
23.Hanania NA, Chapman KR, Kesten S. Adverse effects of inhaled corticosteroids. Am J Med 1995;98:196-207.
24.Kenalog (triamcinolone acetonide) topical aerosol package insert. Jacksonville, FL: Ranbaxy; 2011 July.
25.Triesence (triamcinolone acetonide injection for ophthalmic use) package insert. Fort Worth, TX: Alcon Laboratories, Inc.; 2018 Dec.
26.Murase JE, Heller MM, Butler DC. Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy. J Am Acad Dermatol. 2014;70:401.e1-14. Review.
27.The American Geriatrics Society 2019 Beers Criteria Update Expert Panel. American Geriatrics Society 2019 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc 2019;00:1-21.
28.Health Care Financing Administration. Interpretive Guidelines for Long-term Care Facilities. Title 42 CFR 483.25(l) F329: Unnecessary Drugs. Revised 2015.
29.Zilretta (triamcinolone acetonide extended-release injectable suspension). Burlington, MA: Flexion Therapeutics, Inc.; 2019 Dec.
30.Aristospan (triamcinolone hexacetonide) 5 mg/ml injection package insert. Princeton, NJ: Sandoz Inc.; 2014 Apr.
31.NAEPP Working Group Report on Managing Asthma During Pregnancy. Recommendations for Pharmacologic Treatment-Update 2004. NIH Publication No. 05-3279. Bethesda, MD: U.S. Department of Health and Human Services; National Institutes of Health; National Heart, Lung, and Blood Institute, 2004
32.Greenberger PA, Patterson R. The management of asthma during pregnancy and lactation. Clin Rev Allergy 1987;5:317-24.
33.Ellsworth A. Pharmacotherapy of asthma while breastfeeding. J Hum Lact 1994;10:39-41.
34.Butler DC, Heller MM, Murase JE. Safety of dermatologic medications in pregnancy and lactation: Part II. Lactation. J Am Acad Dermatol. 2014;70:417.e1-10. Review.
35.Trental (pentoxifylline) package insert. Bridgewater, NJ: Sanofi-Aventis Pharmaceuticals Inc.; 2010 Jun.
36.Conn HO, Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. J Intern Med 1994;236:619-32.
37.Abramson N, Melton B. Leukocytosis: basic of clinical assessment. Am Fam Physician 2000;62:2053-60.
38.Shoenfeld Y, Gurewich Y, Gallant LA, et al. Prednisone-induced leukocytosis. Influenced of dosage, method and duration of administration on the degree of leukocytosis. Am J Med 1981;71:773-8.
39.Prednisone tablet package insert. Salisbury, MD: Cadista Pharmaceuticals Inc.; 2016 Mar.
40.Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med 2004;141:764-70.
41.Kenalog-10 (triamcinolone acetonide) injection package insert. Princeton, NJ: Bristol-Myers Squibb Company; 2018 Jun.
42.Cumming RG, Mitchell P, Leeder SR, et al. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med 1997;337:8-14.
43.Trivaris (triamcinolone acetonide injectable suspension) package insert. Irvine, CA: Allergan, Inc.; 2008 Jun.

Legal Disclaimer: All information presented in this website is intended for informational purposes only and not for the purpose of rendering medical advice.